High-flow nasal cannula oxygen therapy to treat patients with hypoxemic acute respiratory failure consequent to SARS-CoV-2 infection.
Andrea VianelloGiovanna ArcaroBeatrice MolenaCristian TuratoAndi SukthiGabriella GuarnieriFrancesca LugatoGianenrico SennaPaolo NavalesiPublished in: Thorax (2020)
This observational study aims to assess the outcome and safety of O2-therapy by high-flow nasal cannula (HFNC) in 28 consecutive patients with severe hypoxemic acute respiratory failure (hARF) consequent to SARS-CoV-2 infection, unresponsive to conventional O2-therapy. Nineteen patients had a positive response. Nine patients required escalation of treatment to non-invasive ventilation (five subsequently intubated). None of the staff had a positive swab testing during the study period and the following 14 days. Severity of hypoxemia and C reactive protein level were correlated with HFNC failure. These data suggest HFNC to be a safe treatment for less severe patients with SARS-CoV-2 hARF and efficacy will need to be assessed as part of a clinical trial.
Keyphrases
- long term care
- respiratory failure
- extracorporeal membrane oxygenation
- mechanical ventilation
- end stage renal disease
- clinical trial
- sars cov
- ejection fraction
- newly diagnosed
- acute respiratory distress syndrome
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- randomized controlled trial
- intensive care unit
- open label
- machine learning
- coronavirus disease
- cell therapy
- patient reported